Research programme: cytokine inhibitors - Bioniz

Drug Profile

Research programme: cytokine inhibitors - Bioniz

Alternative Names: BJNZ132-2; BNZ 2; BNZ 3; BNZ132-3

Latest Information Update: 08 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bioniz
  • Class Peptides
  • Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 4 receptor antagonists; Interleukin 9 receptor antagonists; Interleukin receptor common gamma subunit inhibitors; Interleukin-21 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis
  • Research Autoimmune disorders; Coeliac disease

Most Recent Events

  • 08 Aug 2016 Early research in Autoimmune disorders in USA (unspecified route) (Bioniz Therapeutics pipeline, August 2016)
  • 08 Aug 2016 Early research in Coeliac disease in USA (PO) (Bioniz Therapeutics pipeline, August 2016)
  • 17 Jun 2015 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top